Related Experiment Video

Updated: Jul 5, 2026

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Published on: July 17, 2020

The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications

Amancio Carnero1, Carmen Blanco-Aparicio, Oliver Renner

  • 1Experimental Therapeutics Programme, Spanish National Cancer Centre (CNIO), C/Melchor Fernandez Almagro 3, 28029 Madrid, Spain. acarnero@cnio.es

Current Cancer Drug Targets
|May 14, 2008
PubMed

Insights

The PTEN/PI3K/AKT pathway is crucial for cell signaling and is frequently altered in cancer. Targeting this pathway offers significant potential for developing new anti-cancer drugs.

Area of Science:

  • Molecular Biology
  • Oncology
  • Biochemistry

Background:

  • The PTEN/PI3K/AKT pathway regulates fundamental cellular processes including apoptosis, metabolism, proliferation, and growth.
  • PTEN, a phosphatase, acts on phosphatidyl-inositol,3,4,5 triphosphate (PIP3), a product of PI3K, influencing AKT activation.
  • Dysregulation of this pathway is implicated in numerous human cancers.

Purpose of the Study:

  • To review the role of the PTEN/PI3K/AKT pathway in biological processes and cancer.
  • To highlight the significance of pathway components as drivers of tumorigenesis.
  • To underscore the therapeutic potential of targeting the PTEN/PI3K/AKT pathway in cancer drug discovery.

Main Methods:

  • Literature review of studies on the PTEN/PI3K/AKT pathway.
  • Analysis of genetic alterations (mutations, deletions, methylation) affecting pathway components in cancer.
  • Examination of functional consequences of pathway dysregulation in cellular and tumor models.

Main Results:

  • PTEN loss (via mutation, deletion, or methylation) is common in various cancers.
  • Activating mutations in PI3K and AKT promote tumorigenesis.
  • PTEN germline mutations are associated with familial cancer predisposition syndromes.
  • Oncogenic Ras transformation depends on PI3K binding.

Conclusions:

  • The PTEN/PI3K/AKT pathway is a critical regulator of cell signaling and a significant contributor to cancer development.
  • Alterations in PTEN, PI3K, and AKT are prevalent in human malignancies.
  • The PTEN/PI3K/AKT pathway represents a promising and important target for novel cancer therapeutics.

More Related Videos

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...